Sandoz has announced the launch of Glatopa (glatiramer acetate injection) 40 mg/mL, a fully-substitutable AP-rated generic version of Copaxone, for the treatment of patients with relapsing forms of multiple sclerosis (MS).
In addition to the 40 mg/mL strength, Glatopa is also available as a 20 mg/mL injection, allowing for a complete range of dosing options for MS patients. Glatiramer acetate is thought to act by modifying immune processes that are believed to be responsible for the pathogenesis of MS.
“The approval and launch of Glatopa 40 mg/mL reinforces our leadership in delivering complex, differentiated generic products,” said Richard Francis, Sandoz, CEO.
Sandoz is a division of the Novartis Group, which focuses on generics and biosimilars. Sandoz GlatopaCare will offer a $0 co-pay support program to qualified patients.
Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis [press release]. Holzkirchen, Germany: Sandoz. Published February 13, 2018. Accessed February 21, 2018.
This article originally appeared on MPR